What is the half-life of amlodipine (amlo)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Half-Life of Amlodipine

Amlodipine has a terminal elimination half-life of approximately 30-50 hours, which is one of the longest among calcium channel blockers and enables true once-daily dosing with sustained blood pressure control. 1

Pharmacokinetic Profile

The elimination characteristics of amlodipine are distinctive among dihydropyridine calcium antagonists:

  • The terminal elimination half-life ranges from 30-50 hours in patients with normal hepatic function 1
  • The elimination half-life extends to 40-60 hours in some studies, with steady-state plasma levels reached after 7-8 days of consecutive daily dosing 2
  • This slow elimination rate results from amlodipine being a low-clearance drug with extensive hepatic metabolism (approximately 90% converted to inactive metabolites) 1, 2

Clinical Implications of the Long Half-Life

The extended half-life confers several clinically relevant characteristics:

  • Plasma concentration fluctuation between doses is only 20-25% with once-daily dosing, providing stable drug levels throughout the 24-hour period 2
  • Blood pressure control is maintained for more than 24 hours following a single dose, offering protection even if a dose is missed 3
  • In chemical adherence testing, amlodipine can remain analytically positive up to a week after the last ingestion, making it difficult to distinguish between regular and sporadic dosing 4
  • Discontinuation results in a gradual return of blood pressure to baseline over 7-10 days with no rebound effect 2, 5

Special Populations

The half-life is significantly affected by hepatic function:

  • In patients with hepatic insufficiency, the plasma elimination half-life extends to 56 hours, requiring dose titration and potentially lower initial doses 1
  • Elderly patients experience decreased clearance with a 40-60% increase in AUC, though the specific half-life extension is not quantified 1
  • Renal impairment does not significantly influence amlodipine pharmacokinetics, as only 10% of the parent compound is excreted renally 1

Comparison to Other Calcium Channel Blockers

The half-life of amlodipine is substantially longer than other dihydropyridines:

  • Amlodipine demonstrates more effective nighttime blood pressure control compared to felodipine extended-release, likely due to its longer elimination half-life 6
  • This extended half-life distinguishes amlodipine from shorter-acting calcium antagonists and contributes to its gradual onset of action (peak plasma concentration at 6-12 hours) 1, 2

Overdose Considerations

The long half-life has important implications in overdose situations:

  • Amlodipine overdose produces prolonged hemodynamic effects requiring extended clinical monitoring 7
  • In a reported case, serum amlodipine concentration remained elevated at 79 ng/mL even 35 hours after ingestion, demonstrating the drug's persistence 7
  • Patients with amlodipine overdose require aggressive decontamination therapy and may need extended supportive care if hemodynamically unstable 7

References

Research

Amlodipine in the current management of hypertension.

Journal of clinical hypertension (Greenwich, Conn.), 2023

Guideline

Amlodipine Elimination and Adherence

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Amlodipine overdose.

The Annals of pharmacotherapy, 1997

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.